Poly(ADP-ribose)polymerase inhibitors for ovarian cancer treatment: Research advances / 国际药学研究杂志

Ovarian cancer is the leading cause of death in women suffering from cancer, with a high mortality rate in gynecological cancer. Poly(ADP-ribose)polymerase(PARP)inhibitors cause targeted tumor cell death in homologous recombination(HR)-deficient cancers, including breast cancer susceptibility gene(BRCA)tumors, and the mechanism is called “synthetic lethality”. At present, there are three PARP inhibitors approved by FDA for the treatment of advanced ovarian cancer with BRCA-mutation. This paper reviews the role of PARP inhibitors in the treatment of ovarian cancer in clinical trial, elaborates the therapeutic mechanism of PARP inhibitors, and lights the way for the development of anti-ovarian cancer drugs.